Topline Results From BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only (HG Ta/T1), BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Janet Kukreja, MD
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Presented at South Central Sectional AUA Meeting
September 11, 2026
Tucson, Arizona

University of Colorado **Anschutz**

Disclosures

- None related to CG Oncology
- Intuitive surgical

Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action



Significant Unmet Need for BCG-UR Papillary (HG Ta/T1) NMIBC

- Current FDA approved agents for patients with HR BCG-UR NMIBC **with CIS +/- Ta/T1**[1]
- Patients commonly present with HG Ta/T1 NMIBC[2-3]
- **Benchmarks reported from recent meta-analysis for BCG-UR HG Ta/T1 NMIBC**[4]
  - 73% at 3 mo
  - 58% at 6 mo
  - 48% at 12 mo

DFS/HG-RFS	Pembrolizumab [5]	Nadofaragene [6,7]	N-803+BCG [8,9]	TAR-200 [10]
3 months, % (95% CI)	87.7 (80.7-92.3)	72.9 (58.2-84.7)	Not Reported	Not Reported
6 months, % (95% CI)	53.1 (44.1-61.2)	62.5 (47.4-76.0)	Not Reported	85.3 (71.6-92.7)
9 months, % (95% CI)	Not Reported	58.3 (43.2–72.4)	Not Reported	81.1 (66.7-89.7)
12 months, % (95% CI)	43.5 (34.9-51.9)	43.8 (29.5-58.8)	55.4 (42.0-66.8)	70.2 (51.6-82.8)
24 months, % (95% CI)	34.9 (26.4-43.4)	33.3 (20.4-48.4)	48.3 (34.5-60.7)	Not Reported

Data are presented for benchmarking purposes only; differences in trial design, patient populations, and endpoints preclude direct cross-trial comparison.

There remains a significant unmet need for clinically effective and well-tolerated bladder-sparing treatment options for the BCG-UR papillary-only NMIBC population

University of Colorado **Anschutz**

BCG- Bacillus Calmette Guerin; CIS +/- Ta/T1- Carcinoma in situ, with or without Ta/T1; NMIBC- Non-Muscle Invasive Bladder Cancer

1 Holzbeierlein J et al., AUA/SUO guideline: 2024 amendment. 2. Nielsen et al 2014. *Cancer*. 2014 3. Taylor J. Long Term Outcomes of Bladder Sparing Therapy Compared to Upfront Radical Cystectomy in BCG Unresponsive NMIBC in an International Cohort . Presented at: SUO 2023. 4.Rose KM, et al. *SIUJ*. 2022;3(5):333-339 5. Necchi A, et al. *Lancet Oncology*. 2024; 25(6):720-730. 6. Boorjian S, et al. *Lancet Oncology*. 2021; 22(1):107-117. 7. Narayan VM, et al. *J Urol*. 2024;212(1):74-86. 8. Chamie K, et al. *NEJM Evid*. 2023; 2(1):EVIDoa2200167. 9. Chang S, et al. *J Urol*. 2026;215(1):44-56. 10. Daneshmand S, et al. Presented at SUO 2025 Annual Meeting.

BOND-003 Cohort P- Papillary Only (HG Ta/T1), BCG-UR, HR-NMIBC

Cohort C (N=112):

- Age ≥ 18 yo
- ECOG PS 0-2
- Pathologically confirmed BCG-UR HR-NMIBC with CIS +/- papillary disease

Primary Endpoint
CR at any time

Secondary Endpoints
Duration of Response
CFS, RFS, PFS

Cohort P (N=56):

- Age ≥ 18 yo
- Pathologically confirmed HR BCG-UR NMIBC HG Ta/T1 (Without CIS)
- Completely resected prior to treatment

Primary Endpoint
HGEFS

Secondary Endpoints
RFS, PFS, CFS, CSS



University of Colorado Anschutz

BOND-003 COHORT P Patient Demographics & Baseline Characteristics

Patients in Safety Dataset	N=56	%
Gender		
Male	44	78.6
Female	12	21.4
Age (Years)		
Mean (SD)	71.6 (9.3)	
Median (Range)	74.0 (45-87)	
Age (Categories)		
< 65	13	23.2
≥ 65 and < 75	18	32.1
≥75	25	44.6
ECOG PS		
ECOG PS 0	48	85.7
ECOG PS 1	8	14.3
HR NMIBC T-Stage at Study Entry		
HG Ta	33	58.9
HG T1	23	41.1
BCG History: No. of Prior Instillations		
Median (Range)	9.0 (5 – 21)	

- Majority of patients are:
  - Male (78.6%)
  - White (87.5%)
  - > 65 years (75%)
- 96.4% of patients in US
- High-Risk population enrolled, with 41.1% HG T1 at baseline

Topline Results: BOND-003 Cohort P HR, Papillary-Only (HG Ta/T1) BCG-Unresponsive NMIBC

- Median follow-up: 6.0 months
- 8 patients were re-induced at 3 months
- Consistent and high HG-EFS
  - HG-Ta:
    - 92.8% (3 mo)
    - 75.9% (6 mo)
    - 75.9% (9 mo)
  - HG-T1:
    - 100% (3 mo)
    - 100% (6 mo)
    - 87.5% (9 mo)
- No patients underwent RC
- No progression to MIBC*



HR= High-Risk; HG-RFS= High-Grade Recurrence-Free Survival; NMIBC= Non-Muscle Invasive Bladder Cancer; RC= Radical Cystectomy
01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.
HG-EFS time from first study treatment (first re-induction dose) to high-grade recurrence, progression, death, or censoring.
* 1 pt progressed to metastatic urothelial carcinoma despite clinical complete response in the bladder.

Consistent, Favorable and Well-Tolerated Safety Profile

Preferred Term (MedDRA v.26.1)	Cretostimogene (n=56)	
	Any Grade (%)	Grade ≥ 3
Patients with ≥ 1 TRAE	40 (71.4%)	0 (0)
Treatment-Related AE reported in > 10% patients		
Bladder Spasm	26 (46.4%)	0 (0)
Dysuria	22 (39.3%)	0 (0)
Pollakiuria	14 (25.0%)	0 (0)
Urgency	11 (19.6%)	0 (0)

- Most AEs were Grade 1-2
- 0% Grade ≥ 3 TRAEs, Serious TRAE, deaths
- No dose delays, missed doses due to TRAEs
- No treatment related discontinuations
- 98.2% received all protocol defined treatments

BOND-003 Cohort P: Conclusions

- Topline results with cretostimogene in BOND-003 Cohort P consistently demonstrate
  - Strong HG-EFS at 3, 6, and 9 mo
  - Responses maintained across HGTa and higher-risk, HGT1, populations
  - Well-tolerated safety profile
- Longer-term treatment and follow up ongoing

BOND-003 COHORT P

BCAN 20 Years of Impact

CG ONCOLOGY

University of Colorado Anschutz

THANK YOU

All Bladder Cancer Patients and Their Families
Key Investigators, Study Coordinators, Nurses

Key Collaborators

Siamak Daneshmand, Los Angeles, CA

Timothy Lyon, Jacksonville, FL

Ankeet Shah, Durham, NC

Trinity Bivalacqua, Philadelphia, PA

Amy Luckenbaugh, Nashville, TN

Colin P.N. Dinney, Rochester, NY

Mark Tyson, Phoenix, AZ

CG Oncology

Jee-Hyun Kim

Pat Keegan

Ana Shermolovych

Rob Svatek

Shelja Patel

Sarah Hohl

Vijay Kasturi

This research is funded by CG Oncology, Inc..